A practical chelation protocol based on stratification of thalassemic patients by serum ferritin and magnetic resonance imaging cardiac t2 *

Hemoglobin

Volumn 33, Issue 5, 2009, Pages 323-331

  Ha, Shau Yin ^a   Mok, Amanda Sio Peng ^a   Chu, Winnie Chiu Wing ^b   Raskalkar, Darshana Dattatray ^b   Cheuk, Daniel Ka Leung ^a   Chiang, Alan Kwok Shing ^a   Ho, Marco Ho Kung ^a   Chan, Godfrey Chi Fung ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

^b CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Cardiac T2*; Chelation protocol; Combined therapy; Deferiprone (L1); Deferoxamine (DFO); Serum ferritin (SF); Thalassemia

Indexed keywords

DEFERIPRONE; DEFEROXAMINE; FERRITIN;

ADOLESCENT; ADULT; AGRANULOCYTOSIS; ARTHROPATHY; BLOOD TRANSFUSION; CHILD; CLINICAL PROTOCOL; CONFERENCE PAPER; CONTROLLED STUDY; DRUG WITHDRAWAL; FATIGUE; FEMALE; FERRITIN BLOOD LEVEL; GASTROINTESTINAL SYMPTOM; HEART DISEASE; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; IRON CHELATION; IRON OVERLOAD; LIVER; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; NAUSEA; NEUTROPENIA; NUCLEAR MAGNETIC RESONANCE IMAGING; PRESCHOOL CHILD; RISK FACTOR; SCHOOL CHILD; STOMACH DISCOMFORT; THALASSEMIA MAJOR; TREATMENT DURATION;

ADOLESCENT; ADULT; BETA-THALASSEMIA; CHELATION THERAPY; CHILD; CHILD, PRESCHOOL; CLINICAL PROTOCOLS; DEFEROXAMINE; DRUG THERAPY, COMBINATION; FEMALE; FERRITINS; HUMANS; IRON; IRON CHELATING AGENTS; IRON OVERLOAD; LIVER; MAGNETIC RESONANCE IMAGING; MALE; MYOCARDIUM; PYRIDONES; SIDEROPHORES; YOUNG ADULT;

EID: 70350694434     PISSN: 03630269     EISSN: 1532432X     Source Type: Journal    
DOI: 10.3109/03630260903211979     Document Type: Conference Paper

References (10)

1. Lau YL, Chan LC, Chan YY, et al. Prevalence and genotypes of alpha- and beta-thalassemia carriers in Hong Kong - implications for population screening. N Engl J Med. 1997;336(18): 1298-1301.
2. Borgna-Pignatti C, Cappellini MD, De Stefano P, et al. Survival and complications in thalassemia. Ann NY Acad Sci. 2005;1054:40-47.
3. Ha SY, Chik KW, Ling SC, et al. A randomized controlled study evaluating the safety and efficacy of deferiprone treatment in thalassemia major patients from Hong Kong. Hemoglobin. 2006;30(2): 263-274.
4. Pennell DJ. T2* magnetic resonance and myocardial iron in thalassemia. Ann NY Acad Sci. 2005; 1054:373-378.
5. Lam WW, Au WY, Chu WC, et al. One-stop measurement of iron deposition in the anterior pituitary, liver, and heart in thalassemia patients. J Magn Reson Imaging. 2008;28(1):29-33.
6. Olivieri NF, Nathan DG, MacMillan JH, et al. Survival in medically treated patients with homozygous b-thalassemia. N Engl J Med. 1994;331(9):574-578.
7. Porcu M, Landis N, Salis S, et al. Effects of combined deferiprone and desferrioxamine iron chelating therapy in b-thalassaemia major end-stage heart failure: a case report. Eur J Heart Fail. 2007;9(3):320-322.
8. Tanner MA, Galanello R, Dessi C, et al. A randomized, placebo-controlled, double-blind trial of the effect of combined therapy with deferoxamine and deferiprone on myocardial iron in thalassemia major using cardiovascular magnetic resonance. Circulation. 2007;115(14):1876-1884.
9. Tanner MA, Galanello R, Dessi C, et al. Combined chelation therapy in thalassemia major for the treatment of severe myocardial siderosis with left ventricular dysfunction. J Cardiovasc Magn Reson. 2008;10(1):12.
10. Christoforidis A, Haritandi A, Tsatra I, et al. Four-year evaluation of myocardial and liver iron assessed prospectively with serial MRI scans in young patients with b-thalassaemia major: comparison between different chelation regimens. Eur J Haematol. 2007;78(1):52-57.